We're pouring billions into interventions that make aging more convenient, not less cruel.

Most longevity funding chases lifespan extension through pathways that delay senescence. We get drugs that push the onset of decline outward by 5-10%. That's real, but it's not what we promised. We're compressing morbidity into a narrower window — living vigorously to 92, then deteriorating just as catastrophically as someone did at 75 in 1985. We've tackled the inconvenience, not the disease itself.

Here's the brutal math: fund a trial that adds 2.5 years of healthy life and you get a publication, a biotech valuation, a pathway to FDA approval. Fund research asking whether we're actually reducing total lifetime suffering — measuring not just when decline starts but how severe it gets, how fast it progresses, how much functional capacity remains — and you get silence. Nobody funds that. It's too hard to measure. Doesn't fit the pipeline.

We need to redirect funding toward interventions that change the shape of the curve, not just shift it. That means:

Rejuvenation biology over delay biology. Senolytics, epigenetic reprogramming, and proteostasis restoration aim to reverse damage, not just slow its accumulation. These are harder, riskier, and less patentable — so they get less money.

Combination therapy infrastructure. Aging is multifactorial. We fund single-target drugs because they're easy to test. We desperately need platform funding for rational polypharmacy in model systems.

Outcome measures that capture what actually matters. Not just biomarkers that correlate with age, but measures of physiological reserve, cognitive resilience, and functional capacity under stress. We can't optimize for what we refuse to measure.

The uncomfortable truth: we've built a longevity industry that rewards extending the years people feel okay, while largely ignoring whether we're making the years people feel terrible any less terrible. That's not a moonshot. That's a convenience upgrade.

We can do better. But it requires funders to care about more than publication-ready longevity claims.